Orthofix Medical Reports Q3 2026 Results with Reduced Full-Year Guidance
Orthofix Medical (OFIX) reported third-quarter net sales of $207.9 million, a 2.3% increase on a pro forma constant currency basis. While the company saw strong growth in its Global Limb Reconstruction and Therapeutic Solutions segments—driven by products like FITBONE and TrueLok—these gains were offset by a 5% decline in U.S. Spine Fixation revenue due to market softness and supplier-related instrument delays. The company significantly lowered its full-year guidance for both net sales ($825M–$830M from $845M–$855M) and Adjusted EBITDA ($86M–$88M from $95M–$98M). These revisions reflect execution challenges in the spine segment and an unfavorable product mix. Despite a net loss of $6.1 million, Orthofix improved its Adjusted EBITDA margin to 12.5% and expects a $15 million revenue benefit from a new European distributor arrangement in late 2026.
Tickers: $OFIX
Topics: adjusted EBITDA net loss net sales revenue guidance segment performance
Read the full article at Motley Fool
Part of the story P3 Health Reports Q3 2026 Profitability Turnaround and Increased Full-Year Guidance (7 articles)